Quotes 5-day view Delayed Nasdaq Copenhagen
05/30/2023
05/31/2023
06/01/2023
06/02/2023
06/06/2023
Date
1116(c)
1116.2(c)
1098.6(c)
1081(c)
1124.6
Last
1 196 069
3 586 673
1 401 308
2 055 716
945 986
Volume
-1.90%
+0.02%
-1.58%
-1.60%
+4.03%
Change
Estimated financial data (e) DKK USD
Sales 2023
222 B
31 973 M
31 973 M
Net income 2023
78 204 M
11 247 M
11 247 M
Net cash position 2023
18 156 M
2 611 M
2 611 M
P/E ratio 2023
31,0x
Yield 2023
1,51%
Sales 2024
259 B
37 224 M
37 224 M
Net income 2024
89 524 M
12 875 M
12 875 M
Net cash position 2024
36 303 M
5 221 M
5 221 M
P/E ratio 2024
26,7x
Yield 2024
1,76%
Capitalization
2 425 B
349 B
349 B
EV / Sales 2023
10,8x
EV / Sales 2024
9,23x
Nbr of Employees
57 089
Free-Float
74,8%
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes treatment products (78.9%);
- rare disease treatment products (11.6%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.;
- obesity treatment products (9.5%).
Net sales are distributed geographically as follows:...
Ratings of Novo Nordisk A/S
All news about NOVO NORDISK A/S
News in other languages on NOVO NORDISK A/S
Analyst Recommendations on NOVO NORDISK A/S
NOVO NORDISK A/S - 02/28
The underlying trend is to the upside
BUY
ETFs positioned on NOVO NORDISK A/S ETFs and Trackers with Trackinsight
Novo Nordisk in talks buy controlling stake in Biocorp
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends NOVO NORDISK A/S
Short Term Mid-Term Long Term Trends Bearish Bullish Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
21
Last Close Price
1 081,00 DKK
Average target price
1 143,05 DKK
Spread / Average Target
5,74%
Please enable JavaScript in your browser's settings to use dynamic charts.